Markers for response to immune checkpoint inhibition include relatively high tumor mutation burdens, elevated expression of immune checkpoints such as tumoral programed cell death ligand 1 (PD-L1) and a ‘hot’ or inflamed state characterized by tumor-infiltrating lymphocytes (TILs) [28]. This evidence concerns the gene CD274 and neoplasm.